Home » Alnylam Seeks to Prove RNAi Skeptics Wrong After Layoffs, End of Novartis Deal
Alnylam Seeks to Prove RNAi Skeptics Wrong After Layoffs, End of Novartis Deal
Those … who follow Cambridge, MA-based Alnylam Pharmaceuticals have come to expect the biotech to land major deals with large drug makers related to its gene-silencing drugs.
Xconomy
Xconomy
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May